TLTFF (Theralase Technologies) Research & Development: $1.56 Mil (TTM As of Mar. 2026)


TLTFF Theralase Technologies Inc TLTFF
46 GF Score
Price $0.17
GF Value $0.13
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Research & Development?

Theralase Technologies TLTFF +1.22% 46 Research & Development is $1.56 Mil as of Mar. 2026. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Theralase Technologies's Research & Development for the three months ended in Mar. 2026 was $0.41 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1.56 Mil.

Theralase Technologies  (OTCPK:TLTFF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Theralase Technologies Research & Development Related Terms

Theralase Technologies Research & Development Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Research & Development Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.29 3.15 2.22 1.93 1.78

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.43 0.47 0.24 0.41
TLTFF
46GF Score
Theralase Technologies Inc TLTFF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.56 Mil mean?
Theralase Technologies (TLTFF) has a Research & Development of $1.56 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Research & Development too high?
Theralase Technologies' current Research & Development is $1.56 Mil. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Research & Development compare to ABT and SYK?
Theralase Technologies' Research & Development of $1.56 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Research & Development is $1.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Research & Development is $1.56 Mil. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Research & Development is $1.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (TLTFF) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13. GuruFocus considers Theralase Technologies to be Modestly Overvalued.

Key valuation signals for TLTFF:

  • Research & Development: $1.56 Mil
  • GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TTX:GermanyTLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score

Get the complete analysis for TLTFF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price
$0.13
GF Value